Inhibrx, Inc. Stock price

Equities

INBX

US45720L1070

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
35.15 USD +0.23% Intraday chart for Inhibrx, Inc. +0.43% -7.50%
Sales 2024 * - Sales 2025 * 2M Capitalization 1.67B
Net income 2024 * -199M Net income 2025 * -252M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 835 x
P/E ratio 2024 *
-8.91 x
P/E ratio 2025 *
-8.78 x
Employees 169
Yield 2024 *
-
Yield 2025 *
-
Free-Float 71.24%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.23%
1 week+0.43%
Current month-4.04%
1 month-11.15%
3 months+2.03%
6 months+76.46%
Current year-7.50%
More quotes
1 week
34.89
Extreme 34.89
35.40
1 month
34.25
Extreme 34.25
37.45
Current year
32.04
Extreme 32.04
39.79
1 year
14.31
Extreme 14.305
39.79
3 years
7.67
Extreme 7.67
47.90
5 years
7.67
Extreme 7.67
50.97
10 years
7.67
Extreme 7.67
50.97
More quotes
Managers TitleAgeSince
Founder 45 10-03-31
Chief Executive Officer 57 10-03-31
Director of Finance/CFO 44 18-09-30
Members of the board TitleAgeSince
Director/Board Member 60 18-03-31
Chief Executive Officer 57 10-03-31
Director/Board Member 64 20-05-31
More insiders
Date Price Change Volume
24-03-27 35.15 +0.23% 346,325
24-03-26 35.07 +0.37% 310,268
24-03-25 34.94 +0.14% 349,015
24-03-22 34.89 -0.23% 323,990
24-03-21 34.97 -0.09% 520,906

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Inhibrx, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of biologic therapeutic candidates in oncology and orphan diseases. Its clinical pipeline includes therapeutic candidates, such as INBRX-101, INBRX-109, INBRX-105 and INBRX-106. INBRX-101 is an engineered recombinant human alpha-1 antitrypsin fragment crystallizable (AAT-Fc) fusion protein therapeutic candidate that the Company is developing for the treatment of patients with Alpha-1 Antitrypsin Deficiency (AATD) and acute Graft-versus -host-disease (aGvHD). INBRX-109 is an engineered tetravalent therapeutic candidate targeting death-receptor 5 (DR5), a TNFRSF member, also known as tumor necrosis factor-related apoptosis-inducing ligand or TRAIL receptor 2. INBRX-105 is a conditional tetravelent PD-L1 targeted 4-1BB agonist that is being investigated as a single agent and in combination with Keytruda in patients with locally advanced or metastatic solid tumors.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
35.15 USD
Average target price
35.5 USD
Spread / Average Target
+1.00%
Consensus
  1. Stock
  2. Equities
  3. Stock Inhibrx, Inc. - Nasdaq